Medicare CED’s Possible Link With Expedited Drug Approvals Could Arise At MedCAC Review
This article was originally published in The Pink Sheet Daily
At its next meeting May 16, the Medicare Evidence Development and Coverage Advisory Committee will hear from former CMS and FDA head Mark McClellan, who has supported the notion of linking Medicare’s coverage with evidence development tool with accelerated drug approvals.
You may also be interested in...
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.